Home Use of an Artificial Beta Cell in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The feasibility, safety, and efficacy of prolonged use of an artificial beta cell (closed-loop insulin-delivery system) in the home setting have not been established. METHODS: In two multicenter, crossover, randomized, controlled studies conducted under free-living home conditions, we compared closed-loop insulin delivery with sensor-augmented pump therapy in 58 patients with type 1 diabetes. The closed-loop system was used day and night by 33 adults and overnight by 25 children and adolescents. Participants used the closed-loop system for a 12-week period and sensor-augmented pump therapy (control) for a similar period. The primary end point was the proportion of time that the glucose level was between 70 mg and 180 mg per deciliter for adults and between 70 mg and 145 mg per deciliter for children and adolescents. RESULTS: Among adults, the proportion of time that the glucose level was in the target range was 11.0 percentage points (95% confidence interval [CI], 8.1 to 13.8) greater with the use of the closed-loop system day and night than with control therapy (P<0.001). The mean glucose level was lower during the closed-loop phase than during the control phase (difference, -11 mg per deciliter; 95% CI, -17 to -6; P<0.001), as were the area under the curve for the period when the glucose level was less than 63 mg per deciliter (39% lower; 95% CI, 24 to 51; P<0.001) and the mean glycated hemoglobin level (difference, -0.3%; 95% CI, -0.5 to -0.1; P=0.002). Among children and adolescents, the proportion of time with the nighttime glucose level in the target range was higher during the closed-loop phase than during the control phase (by 24.7 percentage points; 95% CI, 20.6 to 28.7; P<0.001), and the mean nighttime glucose level was lower (difference, -29 mg per deciliter; 95% CI, -39 to -20; P<0.001). The area under the curve for the period in which the day-and-night glucose levels were less than 63 mg per deciliter was lower by 42% (95% CI, 4 to 65; P=0.03). Three severe hypoglycemic episodes occurred during the closed-loop phase when the closed-loop system was not in use. CONCLUSIONS: Among patients with type 1 diabetes, 12-week use of a closed-loop system, as compared with sensor-augmented pump therapy, improved glucose control, reduced hypoglycemia, and, in adults, resulted in a lower glycated hemoglobin level. (Funded by the JDRF and others; AP@home04 and APCam08 ClinicalTrials.gov numbers, NCT01961622 and NCT01778348.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Medtronic 780G, 113,114 CamAPS FX, 115,116 and Diabeloop 117 received CE mark for use in European countries;”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [115]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
The barrier of hypoglycemia in diabetes
Cryer, P. E. (2008) · Diabetes · doi:10.2337/db08-1084 · Cited by 725
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 3×
“Hyperglycemia related to infusion-set occlusion 0 6 (18) 4 (12) 0 0 2 (8) 0 0”
Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
Russell, S. J., El-Khatib, F. H., Sinha, M., Magyar, K. L., McKeon, K., Goergen, L. G., Balliro, C., Hillard, M. A., Nathan, D. M., & Damiano, E. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314474 · Cited by 602 · cited 2×
“Hyperglycemia related to infusion-set occlusion 0 6 (18) 4 (12) 0 0 2 (8) 0 0”
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541
Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes Camp
Phillip, M., Battelino, T., Atlas, E., Kordonouri, O., Bratina, N., Miller, S., Biester, T., Avbelj Stefanija, M., Muller, I., Nimri, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1206881 · Cited by 435
Wood, J. R., Miller, K. M., Maahs, D. M., Beck, R. W., DiMeglio, L. A., Libman, I. M., Quinn, M., Tamborlane, W. V., Woerner, S. E., & for the T1D Exchange Clinic Network (2013) · Diabetes Care · doi:10.2337/dc12-1959 · Cited by 415
Ly, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411
McKnight, J. A., Wild, S. H., Lamb, M. J. E., Cooper, M. N., Jones, T. W., Davis, E. A., Hofer, S., Fritsch, M., Schober, E., Svensson, J., et al. (2015) · Diabetic Medicine · doi:10.1111/dme.12676 · Cited by 343 · cited 6×
“Knee-joint arthralgia 0 1 (3) 0 0 0 0 0 0”
InfluentialClosed-loop insulin delivery from bench to clinical practice
Hovorka, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.32 · Cited by 342 · cited 1×
“Gastroenteritis 0 2 (6) 3 (9) 0 0 0 0 0”
Self-citation
Cited by
Items 201–300 of 454
Pinckney, A., Rigby, M. R., Keyes-Elstein, L., Soppe, C. L., Nepom, G. T., & Ehlers, M. R. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.04.032 · Cited by 28
“9% range and rates of hypoglycemia are not improved compared with sensor-augmented pump therapy.(43,44) A recent analysis from the T1D Exchange indicated that most youth with T1D do not meet the HbA1c targets recommended by the American Diabetes Association (o7.”
Fushimi, E., Rosales, N., Battista, H. D., & Garelli, F. (2018) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2018.05.009 · Cited by 26
Coutant, R., Bismuth, É., Bonnemaison, É., Dalla‐Vale, F., Morinais, P., Perrard, M., Trely, J., Faure, N., Bouhours‐Nouet, N., Levaillant, L., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0518 · Cited by 26
Development and Future of Automated Insulin Delivery (AID) Systems
Garg, S. K., & MCVEAN, J. J. F. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0467 · Cited by 28
Boggi, U., Vistoli, F., Marchetti, P., Kandaswamy, R., & Berney, T. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16738 · Cited by 28
A simple modeling framework for prediction in the human glucose–insulin system
Sirlanci, M., Levine, M. E., Wang, C. C. L., Albers, D. J., & Stuart, A. M. (2023) · Chaos An Interdisciplinary Journal of Nonlinear Science · doi:10.1063/5.0146808 · Cited by 25
Closed-loop insulin delivery: current status of diabetes technologies and future prospects
Majeed, W., & Thabit, H. (2018) · Expert Review of Medical Devices · doi:10.1080/17434440.2018.1503530 · Cited by 27
“Based on the authors own experience of CLS use in real-world settings [69,72], patient expectations have to be carefully considered and managed.”
BackgroundSelf-citationOptimal regulation of blood glucose level in Type I diabetes using insulin and glucagon
Shirin, A., Rossa, F. D., Klickstein, I. S., Russell, J. J., & Sorrentino, F. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213665 · Cited by 27
“In [15–18, 25] a linear model predictive control (MPC) has been used in a model with fixed structure but for which parameters are constantly updated to adapt to the patient’s response.”
MethodTaylor, M. J., Gregory, R., Tomlins, P. E., Jacob, D., Hubble, J., & Sahota, T. S. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.12.024 · Cited by 27
The closed‐loop artificial pancreas in 2020
Fabris, C., & Kovatchev, B. P. (2020) · Artificial Organs · doi:10.1111/aor.13704 · Cited by 24
Glucose-lowering therapies in type 2 diabetes: Opportunities and challenges for peptides
Bailey, C. J. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.012 · Cited by 24
“adjust insulin dose have been successfully trialled in type 1 diabetes [17, 18].”
A Crossover Design for Comparative Efficacy
Wiley, H. E., Thompson, D. J. S., Bailey, C., Chew, E. Y., Cukras, C. A., Jaffe, G. J., Lee, R., Loken, E. K., MEYERLE, C. B., Wong, W. T., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.11.021 · Cited by 23
Cordero, T. L., Garg, S. K., Brazg, R., Bailey, T. S., Shin, J., Lee, S. W., & KAUFMAN, F. R. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0208 · Cited by 25
“, in-home) randomized and controlled feasibility studies comparing SAP or conventional insulin pump use to HCL or CL system use (from, at least, 4 days to 6 months) have reported improved overall in-target SG values, SG variability,(15,17) or HbA1c levels.(13,17) While these studies involved run-in periods ranging fro…”
MethodRuan, Y., Bally, L., Thabit, H., Leelarathna, L., Hartnell, S., Tauschmann, M., Wilinska, M. E., Evans, M. L., Mader, J. K., Kojzar, H., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13304 · Cited by 22
“14] U/kg).(7,8) Participants were randomly assigned to receive, in a crossover randomized fashion, hybrid day-and-night closed-loop insulin delivery and sensor-augmented (32 participants) or conventional (28 participants) pump therapy.”
MethodSelf-citationRidder, F. D., den Brinker, M., & Block, C. E. M. D. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819865399 · Cited by 23
Cobelli, C., & Man, C. D. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211015268 · Cited by 24
Automated blood glucose control in type 1 diabetes: A review of progress and challenges
Bertachi, A. H., Ramkissoon, C. M., Bondía, J., & Vehí, J. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.03.001 · Cited by 30
Materials and System Design for Self‐Decision Bioelectronic Systems
Zeng, Q., Liu, H., Zhang, Y., Zheng, Y., Ding, X., Zhu, M., Shi, G., Wang, Y., Haick, H., & Zhang, M. (2026) · Advanced Materials · doi:10.1002/adma.202521164 · Cited by 33
Bertachi, A. H., Beneyto, A., Ramkissoon, C. M., & Vehí, J. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0392 · Cited by 23
Cherubini, V., Gesuita, R., Skrami, E., Rabbone, I., Bonfanti, R., Arnaldi, C., d’Annunzio, G., Frongia, A., Lombardo, F., Piccinno, E., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12792 · Cited by 25
“The coefficient of variation of BG over the three-day period was low and comparable with the variability showed by the bionic pancreas in a 5-day experiment with 32 adolescents during a summer camp(11) and a close loop system used at home during a 12-week period in 25 children and adolescents.(10) These all show that…”
MethodModeling Glucagon Action in Patients With Type 1 Diabetes
Emami, A., Youssef, J. E., Rabasa-Lhoret, R., Pineau, J., Castle, J. R., & Haidar, A. (2017) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2016.2593630 · Cited by 20
“Two configurations of closed-loop systems have been proposed: those that infuse insulin (single-hormone systems) [11] and those that infuse insulin and glucagon (dual-hormone systems) [12]–[14].”
BackgroundRigla, M., Pons, B., Rebasa, P., Luna, A., del Pozo, F. J. D., Caixàs, A., Villaplana, M., Subías, D., Bella-Cueto, M. R., & Combalía, N. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0321 · Cited by 23
Patient Perception and Satisfaction With Insulin Pump System: Pilot User Experience Survey
Grando, A., Bayuk, M., Karway, G. K., Corrette, K., Groat, D., Cook, C. B., & Thompson, B. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819843146 · Cited by 21
Leelarathna, L., Thabit, H., Willinska, M. E., Bally, L., Mader, J., Arnolds, S., Benesch, C., Pieber, T., Shah, V. N., Carlson, A. L., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2041 · Cited by 17
“night, hybrid closed-loop studies (2,3) (AP@home04 and APCam11) of 12 weeks’ duration (N 5 56, mean 6 SD A1C 68 6 7 mmol/mol [8.”
MethodSelf-citationModelling glucose dynamics during moderate exercise in individuals with type 1 diabetes
Alkhateeb, H., Fathi, A. E., Ghanbari, M., & Haidar, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248280 · Cited by 23
“Randomized clinical trials have shown that the artificial pancreas improves glucose control and reduces hypoglycemia [4].”
BackgroundThe Feasibility and Applicability of Stem Cell Therapy for the Cure of Type 1 Diabetes
Inoue, R., Nishiyama, K., Li, J., Miyashita, D., Ono, M., Terauchi, Y., & Shirakawa, J. (2021) · Cells · doi:10.3390/cells10071589 · Cited by 23
Thabit, H., & Hovorka, R. (2018) · Diabetic Medicine · doi:10.1111/dme.13563 · Cited by 22
Self-citationJoseph, J. I., EISLER, G. J., Diaz, D., Khalf, A., Loeum, C., & Torjman, M. C. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0106 · Cited by 22
Pease, A., Andrikopoulos, S., Abraham, M. B., Craig, M. E., Fenton, B., Overland, J., Price, S., Simmons, D. S., & Ross, G. P. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.51118 · Cited by 20
Closed‐loop technology: a practical guide
Hartnell, S., Fuchs, J., Boughton, C. K., & Hovorka, R. (2021) · Practical Diabetes · doi:10.1002/pdi.2350 · Cited by 22
Self-citationMorrison, D., Paldus, B., Zaharieva, D. P., Lee, M. H., Vogrin, S., Jenkins, A. J., Gerche, A. L., MacIsaac, R. J., McAuley, S. A., Ward, G. M., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0279 · Cited by 19
Pathophysiology and management of hypoglycemia in diabetes
RANGEL, E. S., Deajon-Jackson, J. D., & Hwang, J. J. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14904 · Cited by 21
Diagnosing cystic fibrosis-related diabetes: current methods and challenges
Prentice, B. J., Hameed, S. A., Verge, C. F., Ooi, C. Y., Jaffé, A., & Widger, J. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1190646 · Cited by 19
“Closed-loop pumps show great promise for future use in many forms of diabetes [113], but especially in CF where optimizing glucose levels whilst minimizing treatment burden”
BackgroundArtificial Pancreas or Novel Beta-Cell Replacement Therapies: a Race for Optimal Glycemic Control?
Nijhoff, M. F., & de Koning, E. J. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1073-6 · Cited by 20
Pinsker, J. E., Dassau, E., Deshpande, S., Raghinaru, D., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Church, M. M., Desrochers, H., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0084 · Cited by 18
Self-citationMPC Model Individualization in Free-Living Conditions: A Proof-of-Concept Case Study
Toffanin, C., Favero, S. D., Aiello, E. M., Messori, M., Cobelli, C., & Magni, L. (2017) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2017.08.271 · Cited by 18
Dunger, D. B. (2016) · Diabetic Medicine · doi:10.1111/dme.13299 · Cited by 18
Self-citationContinuous glucose monitoring: a systematic review of sensor systems and prospects
Ray, P. P. (2018) · Sensor Review · doi:10.1108/sr-12-2017-0268 · Cited by 20
Tschaikner, M., Powell, K., Jungklaus, M., Fritz, M., Ellmerer, M., Hovorka, R., Lane, S., Pieber, T. R., & Regittnig, W. (2019) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2019.2925434 · Cited by 19
“Indeed, a considerable number of studies have demonstrated safety and effectiveness of such AP systems both in the clinical research center (CRC) and the outpatient environment [7]–[10].”
BackgroundResultSelf-citationBally, L., Thabit, H., Tauschmann, M., Allen, J. M., Hartnell, S., Wilinska, M. E., Exall, J., Huegel, V., Sibayan, J., Borgman, S. K., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016738 · Cited by 17
Self-citationThe Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus
Giorgino, F., Battelino, T., Bergenstal, R. M., Forst, T. M., Green, J. B., Mathieu, C., Rodbard, H. W., Schnell, O., & Wilmot, E. G. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231204584 · Cited by 20
“58,59 URAA as even faster-acting insulins may allow the device to respond more quickly to elevated glucose levels and have therefore been investigated in a small number of clinical studies.”
Schliess, F., Heise, T., Benesch, C., Mianowska, B., Stegbauer, C., Broge, B., Gillard, P., Binkley, G., Crône, V., Carlier, S., et al. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818803588 · Cited by 17
“0 mmol/l) was significantly higher in both adults and children/adolescents, accompanied by reduced time in hypoglycemia and no change in total daily insulin doses when using the experimental AP system developed by the consortium.(6) The AP@home initiative also demonstrated a significant reduction of HbA1c (–0.”
MethodSelf-citationBally, L., Herzig, D., Ruan, Y., Wilinska, M. E., Semmo, M., Vogt, A. P., Wertli, M. M., Vogt, B., Stettler, C., & Hovorka, R. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13861 · Cited by 17
“Closed-loop insulin delivery is an emerging therapeutic modality that titrates insulin in response to sensor glucose levels and has been shown to improve glucose control across populations and ages of subjects with type 1 to type 2 diabetes.(6-10) In a post hoc analysis of an outpatient hybrid closed-loop study, a sho…”
BackgroundSelf-citationBoughton, C. K., Allen, J. M., Tauschmann, M., Hartnell, S., Wilinska, M. E., Musolino, G., Acerini, C. L., Dunger, D. B., Campbell, F., Ghatak, A., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-033500 · Cited by 18
Self-citationAsadi, S., & Nekoukar, V. (2018) · Mathematical Biosciences · doi:10.1016/j.mbs.2018.09.006 · Cited by 17
Emami, A., Wilinska, M. E., Thabit, H., Leelarathna, L., Hartnell, S., Dellweg, S., Benesch, C., Mader, J. K., Holzer, M., Kojzar, H., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0307 · Cited by 16
“Detailed information regarding the study design and results has been published.(8)”
BackgroundMethodInfluentialSelf-citationHypoglycemia Prevention via Personalized Glucose-Insulin Models Identified in Free-Living Conditions
Toffanin, C., Aiello, E. M., Cobelli, C., & Magni, L. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819880864 · Cited by 16
Development platform for artificial pancreas algorithms
Smaoui, M. R., RABASA-LHORET, R. P. R., & Haidar, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243139 · Cited by 18
Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy
Pasqua, M., Tsoukas, M. A., & Haidar, A. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211035411 · Cited by 18
Hypoglycaemia‐free artificial pancreas project
Magdelaine, N., Rivadeneira, P. S., Chaillous, L., Fournier‐Guilloux, A., Krempf, M., MohammadRidha, T., Ahmed, M. A., & Moog, C. H. (2019) · IET Systems Biology · doi:10.1049/iet-syb.2018.5069 · Cited by 19
Resalat, N., Youssef, J. E., Reddy, R., & Jacobs, P. G. (2017) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2017.08.2270 · Cited by 15
Ali, Z., Valk, T., Bjerre‐Christensen, T., Brandt, S., Ísberg, A. P., Jensen, M. L., Helledi, L. S., Kaas, A., Thomsen, S. F., Andersen, A. D., et al. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211045656 · Cited by 15
“Age, years, mean (SD) 57 (7) 58 (7) 57 (8) 0.”
Automated Insulin Delivery in Pregnancies Complicated by Type 1 Diabetes
Benhalima, K., & Polsky, S. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251323614 · Cited by 17
“7,22,23 This AID system contains a treat-to-target adaptive model predictive control (MPC) algorithm.”
Mise en place de l’insulinothérapie automatisée en boucle fermée : position d’experts français
Franc, S., Schaepelynck, P., Tubiana‐Rufi, N., Chaillous, L., Joubert, M., Renard, É., Reznik, Y., Abettan, C., Bismuth, É., Beltrand, J., et al. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(20)30003-1 · Cited by 24
Elbarbary, N. S., & Ismail, E. A. R. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01232-5 · Cited by 15
“These systems use a mathematical dosing algorithm that takes real-time data from a continuous glucose monitor to titrate infusion by an insulin pump [12].”
BackgroundMusolino, G., Allen, J. M., Hartnell, S., Wilinska, M. E., Tauschmann, M., Boughton, C. K., Campbell, F., Denvir, L., Trevelyan, N., Wadwa, P., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027856 · Cited by 16
“So far, evaluations have been limited to 3 months.(22) The present study will assess the efficacy, safety, utility and acceptability of 6-month day-and-night hybrid closedloop insulin delivery during unrestricted living in comparison to usual care in children and adolescents with type 1 diabetes.”
Self-citationEberle, C., Löhnert, M., & Stichling, S. (2021) · Journal of Medical Internet Research · doi:10.2196/24982 · Cited by 15
Graf, A., McAuley, S. A., Sims, C. M., Ulloa, J., Jenkins, A. J., Voskanyan, G. R., & O'Neal, D. N. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816682762 · Cited by 15
Donaldson, L. E., Fourlanos, S., Vogrin, S., MacIsaac, R. J., Colman, P. G., & McAuley, S. A. (2023) · Internal Medicine Journal · doi:10.1111/imj.16143 · Cited by 13
Use of continuous glucose monitoring and hybrid closed‐loop therapy in pregnancy
Benhalima, K., & Yamamoto, J. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15999 · Cited by 15
“6,87,88 The CamAPS ® FX contains a treat-to-target adaptive model predictive controller algorithm.”
Closed-loop insulin delivery systems in children and adolescents with type 1 diabetes
Dovč, K., & Battelino, T. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1713747 · Cited by 15
de Bock, M. I., McAuley, S. A., Abraham, M. B., Smith, G. J., Nicholas, J. A., Ambler, G. R., Cameron, F. J., Fairchild, J. M., King, B. R., Geelhoed, E. A., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020275 · Cited by 15
“The longest duration of follow-up for included studies was 12 weeks.(13) This included two substudies: (1) a study in adults (n=33) who used the system 24 hours per day, and (2) a study in children and adolescents (n=25) who used the system overnight.”
BackgroundMethodAlbers, D. J., Levine, M. E., Mamykina, L., & Hripcsak, G. M. (2019) · Mathematical Biosciences · doi:10.1016/j.mbs.2019.108242 · Cited by 17
100 Years of insulin: Lifesaver, immune target, and potential remedy for prevention
Ziegler, A., Danne, T., Daniel, C., & Bonifacio, E. E. (2021) · Med · doi:10.1016/j.medj.2021.08.003 · Cited by 14
Automated insulin dosing systems: Advances after a century of insulin
Thabit, H., Lal, R., & Leelarathna, L. (2021) · Diabetic Medicine · doi:10.1111/dme.14695 · Cited by 14
Self-citationFeasibility Studies of an Insulin-Only Bionic Pancreas in a Home-Use Setting
Ekhlaspour, L., Nally, L. M., El-Khatib, F. H., Ly, T. T., Clinton, P. K., Frank, E., Tanenbaum, M. L., Hanes, S. J., SELAGAMSETTY, R., Hood, K. K., et al. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819872225 · Cited by 13
Automated Insulin Delivery—The Light at the End of the Tunnel
Turksoy, K., Frantz, N., Quinn, L., Dumin, M., Kilkus, J. M., Hibner, B. A., Çınar, A., & Littlejohn, E. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2017.02.055 · Cited by 14
Quirós, C., Bertachi, A. H., Giménez, M., Biagi, L., Viaplana, J., Viñals, C., Vehí, J., Conget, I., & Bondía, J. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2017.12.012 · Cited by 14
Sehgal, S., de Bock, M. I., Jones, S., Frewen, C. M., & Wheeler, B. J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1214975 · Cited by 12
Marchetti, L., Reali, F., Dauriz, M., Brangani, C., Boselli, L., Ceradini, G., Bonora, E., Bonadonna, R. C., & Priami, C. (2016) · Scientific Reports · doi:10.1038/srep36029 · Cited by 12
Sivasubramaniyam, S., Amiel, S. A., & Choudhary, P. (2017) · Diabetic Medicine · doi:10.1111/dme.13438 · Cited by 12
Xie, J., & Wang, Q. (2018) · Journal of Biomechanical Engineering · doi:10.1115/1.4041522 · Cited by 13
Technology in Diabetes Treatment: Update and Future
Schiel, R., Bambauer, R., & Steveling, A. (2018) · Artificial Organs · doi:10.1111/aor.13296 · Cited by 14
Feedback control algorithms for automated glucose management in T1DM: the state of the art
Shi, D., Deshpande, S., Dassau, E., & Doyle, F. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815655-1.00010-7 · Cited by 17
Saboo, B., Garg, S. K., Bergenstal, R. M., Battelino, T., Ceriello, A., Choudhary, P., de Bock, M. I., Elbarbary, N. S., Forlenza, G. P., Gómez, A. M., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0028 · Cited by 12
Self-citationSteenkamp, D., Brouillard, E., Aia, C., Fantasia, K. L., Sullivan, C. A. W., Atakov-Castillo, A., & Wolpert, H. A. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.04.001 · Cited by 11
Real-Life Use of Automated Insulin Delivery in Individuals With Type 2 Diabetes
Fabris, C., & Kovatchev, B. P. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241274786 · Cited by 11
Allaert, F., Mäzen, N.-J., Legrand, L., & Quantin, C. (2017) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-017-0408-6 · Cited by 11
Grant, A. D., Lewis, D. M., & Kriegsfeld, L. J. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821994825 · Cited by 12
Sperling, M. A., Wolfsdorf, J. I., Menon, R. K., Tamborlane, W. V., Maahs, D. M., Battelino, T., & Phillip, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00021-x · Cited by 13
Meal Detection in the Artificial Pancreas: Implications During Exercise
Ramkissoon, C. M., Herrero, P., Bondía, J., & Vehí, J. (2017) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2017.08.1083 · Cited by 13
Chakrabarty, A., Zavitsanou, S., Sowrirajan, T., Doyle, F. J., & Dassau, E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815655-1.00011-9 · Cited by 11
Artificial pancreas systems: experiences from concept to commercialisation
Rodríguez-Sarmiento, D. L., Vargas, F. M. L., & Maira, G. (2022) · Expert Review of Medical Devices · doi:10.1080/17434440.2022.2150546 · Cited by 11
“Effectiveness of the system integrated into a mobile device in the home [59].”
BackgroundMethodArchinkova, M., Konstantinova, M. M., Savova, R., Iotova, V., Petrova, C., Kaleva, N., Koprivarova, K., Popova, G., Koleva, R., Boyadzhiev, V., et al. (2017) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2017.1379360 · Cited by 14
Where Do We Stand with Closed-Loop Systems and Their Challenges?
Jackson, M. A., & Castle, J. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0469 · Cited by 13
Efficacy and safety of the artificial pancreas in the paediatric population with type 1 diabetes
Esposito, S., Santi, E., Mancini, G., Rogari, F., Tascini, G., Toni, G., Argentiero, A., & Berioli, M. G. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1558-8 · Cited by 11
Jabari, M. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-40423-y · Cited by 11
Bolusing frequency and amount impacts glucose control during hybrid closed‐loop
Bally, L., Thabit, H., Ruan, Y., Mader, J. K., Kojzar, H., Dellweg, S., Benesch, C., Hartnell, S., Leelarathna, L., Wilinska, M. E., et al. (2017) · Diabetic Medicine · doi:10.1111/dme.13436 · Cited by 11
Self-citationSingle-Hormone Artificial Pancreas Use in Diabetes: Clinical Efficacy and Remaining Challenges
Taleb, N., Tagougui, S., & RABASA-LHORET, R. P. R. (2019) · Diabetes Spectrum · doi:10.2337/ds18-0094 · Cited by 11
“(7) compared SH-AP to threshold-suspend insulin pump therapy for 12 weeks in 25 pediatric patients (using SH-AP only at night) and 33 adults (using SH-AP day and night) with type 1 diabetes.”
MethodAng, K. H., & Sherr, J. L. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1360862 · Cited by 11
Kohli, M., Pandey, P., Jakhmola, V., Saha, S., Chaudhary, M., Ansori, A. N. M., & Negi, A. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01648-y · Cited by 10
AP@home: The Artificial Pancreas Is Now at Home
Heinemann, L., Benesch, C., & DeVries, J. H. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816632002 · Cited by 9
“Two final AP@home studies investigated this: The “Hybrid Artificial Pancreas Study” was performed by 3 clinical research centers (Study 1; AMS, MPL, and PAD) and the “AP@home04 Study” was performed in 3 other clinical research centers (Study 2; CAM, GRZ, and PRO).(8,9) The purpose of Study 1 (“Hybrid Artificial Pancre…”
Self-citationDeployment of modular MPC for type 1 diabetes control: the Italian experience 2008–2016
Favero, S. D., Toffanin, C., Magni, L., & Cobelli, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815655-1.00016-8 · Cited by 11
Basal insulin delivery reduction for exercise in type 1 diabetes: finding the sweet spot
Thabit, H., & Leelarathna, L. (2016) · Diabetologia · doi:10.1007/s00125-016-4010-8 · Cited by 9
“home studies [12], but further technological development is needed to optimise its efficacy during exercise.”
BackgroundSelf-citationDe la bomba de insulina y el monitoreo continuo de glucosa al páncreas artificial
Apablaza, P., Néstor Soto, I., & Ethel Codner, D. (2017) · Revista médica de Chile · doi:10.4067/s0034-98872017000500011 · Cited by 18
Insulin therapy for type 2 diabetes – are we there yet? The d-Nav® story
Hodish, I. (2018) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0056-5 · Cited by 10
“A great deal of research have been invested to develop a closed loop system combing an insulin pump and a continuous glucose monitor to form an “artificial pancreas [80].”
BackgroundAutomated Insulin Delivery in Children with Type 1 Diabetes
Cengiz, E. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.012 · Cited by 10
Berget, C., Annan, F., Biester, T., Choudhary, P., Forlenza, G. P., Peters, A. L., Renard, É., & Deiss, D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16321 · Cited by 9
Controlling the AP Controller: Controller Performance Assessment and Modification
Hajizadeh, I., Hobbs, N., Samadi, S., Sevil, M., Rashid, M. M., Brandt, R., Askari, M. R., Maloney, Z., & Çınar, A. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819877217 · Cited by 8
“Despite the proven advantages, fully automated closed-loop control of blood glucose concentration (BGC) using an AP remains challenging because of the needs for (1) reliable models to accurately describe the patient-specific time-varying glucose-insulin dynamics; (2) knowledge of insulin constraints to prevent an over…”
MethodAutomated insulin delivery: what's new, needed, and next?
Murphy, H. R., & Stewart, Z. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32591-0 · Cited by 8
Metadata
- Authors
- Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., Mader, J. K., Holzer, M., Kojzar, H., Exall, J., Yong, J., Pichierri, J., Barnard, K. D., Kollman, C., Cheng, P., Hindmarsh, P. C., Campbell, F. M., Arnolds, S., Pieber, T. R., Evans, M. L., Dunger, D. B., & Hovorka, R.
- Affiliations
- University of Cambridge (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Profil Institute for Metabolic Research (DE)
- Medical University of Graz (AT)
- Leeds Teaching Hospitals NHS Trust (GB)
- University College Hospital (GB)
- Bournemouth University (GB)
- Jaeb Center for Health Research (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2129-2140
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4697362
- OpenAlex
- W2332531077
- Cited by
- 450
- References
- 29
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 23 · 2023: 29 · 2022: 31 · 2021: 43 · 2020: 34 · 2019: 49 · 2018: 71 · 2017: 71 · 2016: 68 · 2015: 10
- FWCI
- 63.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Funders
- Wellcome Trust (100574, 100574/Z/12/Z)
- National Institute for Health and Care Research (NF-SI-0508-10274, NF-SI-0513-10012, CAMBRC-2012-1)
- Swansea University
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, artificial pancreas, artificial beta cell, sensor-augmented pump therapy, glycemic variability, HbA1c, children and adolescents, adults, continuous glucose monitoring, insulin pump therapy, free-living conditions, hypoglycemia risk reduction, glycemic control
- MeSH terms
- Adolescent, Adult, Algorithms, Child, Diabetes Mellitus, Type 1, Equipment Design, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Infusion Pumps, Implantable, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.